(54 days)
CAAS MRV features segmentation of cardiovascular structures on different types of MR images as well as measurement and reporting tools to facilitate the following use:
· Quantitative functional and regional analyses of the heart ventricles
· Quantification of T2 and T2* relaxation values
CAAS MRV is intended to be used by or under supervision of a cardiologist. When the results provided by CAAS MRV are used in a clinical setting to support diagnosis of cardiovascular conditions, the results assurts of critic to be regarded as the sole, irrefutable basis for clinical decision making.
CAAS MRV is designed as a stand-alone modular software package for viewing and quantification of cardiovascular MR images intended to run on a PC with a Windows operating system. The images for analysis can be read from CD, hard disk or from a PACS system and CAAS MRV provides the functionality to scan the contents of a specific directory and to organize the found DICOM MR images into patients, studies and series.
CAAS MRV contains several analysis workflows of the previously cleared predicate device CAAS MRV (K060941) for quantification of the functional and regional parameters of the heart ventricles. Contour detection performed automatically, semi-automatically or manually forms the bases for the analyses.
Functionality to quantify T2 and T2* relaxation values is added by means of the analysis module Tissue Mapping. For this specific feature, Medis MR-CT VVA is used as a predicate device. This feature is implemented in MR-CT VVA and is very similar in both control and presentation, to the CAAS MRV feature, and yields the same results.
The quantitative results of CAAS MRV support diagnosis of cardiovascular conditions.
The analysis results are available on screen and can be saved to hard-disk to enable re-analysis of the data. Also, the analysis results can be exported in various electronic formats.
The functionality is independent of the type of vendor acquisition equipment.
Acceptance Criteria and Device Performance for CAAS MRV (K162112)
Note: The provided document is a 510(k) summary, which generally focuses on demonstrating substantial equivalence to predicate devices rather than detailing extensive clinical trials with specific acceptance criteria and outcome metrics for standalone performance or comparative effectiveness. Therefore, some requested information may not be explicitly present and is inferred where possible.
1. Table of Acceptance Criteria and Reported Device Performance
The document does not explicitly present a table of numerical acceptance criteria. Instead, it describes general validation approaches and claims equivalence rather than specific quantitative performance targets. The "Performance Data" section states that "the quantification of the tissue relaxation values (T2 and T2*) meet the accuracy and reproducibility requirements." However, the specific numerical requirements or the reported accuracy/reproducibility values are not disclosed in this document.
For the purpose of illustrating the expected format, if such a table were present, it might look like this:
| Performance Metric | Acceptance Criteria | Reported Device Performance (as described/implied) |
|---|---|---|
| Quantification of T2/T2 relaxation values (Tissue Mapping)* | [Specific numerical accuracy targets, e.g., < 5% difference from reference standard, or specific correlation coefficient] | "meet the accuracy and reproducibility requirements" (specific numerical values not provided in this document). Implied: Similar to Medis MR-CT VVA. |
| Functional/Regional Analysis of Heart Ventricles | [Specific accuracy and reproducibility targets for LV/RV volumes, ejection fraction, etc., compared to reference] | Regression testing performed to "verify equivalence in numerical results" to previous CAAS MRV (K060941). Implied: Performance is equivalent to the predicate. |
| System Requirements | All defined system requirements implemented correctly. | "System testing showed that the system requirements were implemented correctly." |
| Usability | User able to use CAAS MRV for its intended purpose. | "Usability testing... demonstrated that the user is able to use CAAS MRV for the purpose it was developed for." |
2. Sample Size Used for the Test Set and Data Provenance
The document does not specify the sample size used for the test set. It mentions "validation of the tissue mapping algorithms" and "regression testing" for existing workflows but provides no details on the number of cases or studies involved.
The provenance of the data (country of origin, retrospective or prospective) is not disclosed in this document.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications
This information is not provided in the document.
4. Adjudication Method for the Test Set
The adjudication method is not described in the document.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No mention of an MRMC comparative effectiveness study is made in this document. The submission focuses on demonstrating substantial equivalence, often through technical comparisons and non-clinical performance data, rather than measuring human reader improvement with AI assistance.
6. Standalone Performance Study
The document describes the validation of algorithms and system testing, which implies standalone performance evaluation of the algorithms. For example, "the validation of the tissue mapping algorithms... demonstrated that the quantification of the tissue relaxation values (T2 and T2*) meet the accuracy and reproducibility requirements." This suggests an assessment of the algorithm's performance without a human in the loop making interpretations. However, specific metrics (e.g., sensitivity, specificity, agreement with ground truth for segmentation or measurements) are not quantified in this summary.
7. Type of Ground Truth Used
The type of ground truth used is not explicitly stated. However, given the nature of the device (segmentation, quantification, T2/T2* relaxation values), it is highly likely that:
- For functional and regional analyses of heart ventricles: Ground truth would typically be established by expert manual segmentation and measurements, or potentially by comparison to other validated imaging modalities or techniques. The mention of "regression testing... to verify equivalence in numerical results" suggests comparison against an established reference from the previous version of CAAS MRV.
- For quantification of T2 and T2 relaxation values:* Ground truth would likely involve a reference standard method for calculating T2 and T2* values, potentially derived from accepted mathematical models applied to the raw MR signal data, or comparisons to a validated quantitative imaging system.
8. Sample Size for the Training Set
The sample size for the training set is not provided in this document. Given that CAAS MRV (K060941) was a predicate, some of the algorithms may have been established prior to this submission, and the "Tissue Mapping" module might have involved a separate development and training process.
9. How the Ground Truth for the Training Set Was Established
The document does not describe how the ground truth for the training set was established. This information is typically part of the device's technical documentation but not usually included in a 510(k) summary focused on substantial equivalence.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, with flowing lines extending from the profiles.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 21, 2016
Pie Medical Imaging B.V. % Ms. Annemiek Bouts Regulatory Affairs Coordinator Philipsweg 1. 6227 AJ Maastricht, Limburg NETHERLANDS
Re: K162112 Trade/Device Name: CAAS MRV Regulation Number: 21 CFR 892.2050 Regulation Name: Picture archiving and communications system Regulatory Class: II Product Code: LLZ Dated: July 13, 2016 Received: July 29, 2016
Dear Ms. Bouts:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
{1}------------------------------------------------
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours.
Michael D'Hara
For
Robert Ochs. Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: January 31, 2017 See PRA Statement below.
510(k) Number (if known) K162112
Device Name CAAS MRV
Indications for Use (Describe)
CAAS MRV features segmentation of cardiovascular structures on different types of MR images as well as measurement and reporting tools to facilitate the following use:
· Quantitative functional and regional analyses of the heart ventricles
- · Quantification of T2 and T2* relaxation values
CAAS MRV is intended to be used by or under supervision of a cardiologist. When the results provided by CAAS MRV are used in a clinical setting to support diagnosis of cardiovascular conditions, the results assurts of critic to be regarded as the sole, irrefutable basis for clinical decision making.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
| Submitter/Owner Name | Pie Medical Imaging BV |
|---|---|
| Address | Philipsweg 1, 6227 AJ Maastricht, The Netherlands |
| Phone Number | +31 43 32 81 328 |
| Fax Number | +31 43 32 81 329 |
| Contact Person: | Annemiek Bouts, Regulatory Affairs Coordinator |
| Email Address | Annemiek.Bouts@pie.nl |
| Preparation Date | 19-Sep-16 |
| Trade Name | CAAS MRV |
| Common Name | CAAS MRV |
| Classification: | Classification Name: Image Processing SystemRegulation Class: Class IIRegulation number: 21 CFR 892.2050Classification Product Code: LLZ |
| Predicate Devices | - CAAS MRV (K060941, Image Processing Systems, 21 CFR 892.2050, LLZ)- Medis MR-CT VVA (K140587, Image Processing Systems, 21 CFR 892.2050, LLZ) |
| Device Description | CAAS MRV is designed as a stand-alone modular software package for viewing and quantification of cardiovascular MR images intended to run on a PC with a Windows operating system. The images for analysis can be read from CD, hard disk or from a PACS system and CAAS MRV provides the functionality to scan the contents of a specific directory and to organize the found DICOM MR images into patients, studies and series.CAAS MRV contains several analysis workflows of the previously cleared predicate device CAAS MRV (K060941) for quantification of the functional and regional parameters of the heart ventricles. Contour detection performed automatically, semi-automatically or manually forms the bases for the analyses.Functionality to quantify T2 and T2* relaxation values is added by means of the analysis module Tissue Mapping. For this specific feature, Medis MR-CT VVA is used as a predicate device. This feature is implemented in MR-CT VVA and is very similar in both control and presentation, to the CAAS MRV feature, and yields the same results.The quantitative results of CAAS MRV support diagnosis of cardiovascular conditions.The analysis results are available on screen and can be saved to hard-disk to enable re-analysis of the data. Also, the analysis results can be exported in various electronic formats.The functionality is independent of the type of vendor acquisition equipment. |
| Intended Use | CAAS MRV is a modular software product intended to be used by or under supervision of a cardiologist or radiologist in order to aid in reading and interpreting cardiovascular MR images to support diagnosis of cardiovascular conditions. |
{4}------------------------------------------------
Indications for Use CAAS MRV features segmentation of cardiovascular structures on different types of MR images as well as measurement and reporting tools to facilitate the following use;
- · Quantitative functional and regional analyses of the heart ventricles;
- · Quantification of T2 and T2* relaxation values
CAAS MRV is intended to be used by or under supervision of a cardiologist or radiologist. When the results provided by CAAS MRV are used in a clinical setting to support diagnoses of cardiovascular conditions, the results are explicitly not to be regarded as the sole, irrefutable basis for clinical decision making.
Technological A comparison of the technological characteristics of the predicate and subject Comparison device is given the table below.
| New Device | Predicate Device | Predicate Device | |
|---|---|---|---|
| Device name | CAAS MRV 4.2 | CAAS MRV (3.0) | MR-CT-VVA |
| Manufacturer | Pie Medical Imaging | Pie Medical Imaging | Medis |
| 510(k) number | - | K060941 | K140587 |
| Imagessupported | Vendor-independent DICOM MRimages (specific requirements dependon type of analysis, but image viewingis possible on all MR images) | Vendor-independent DICOM MRimages (specific requirements dependon type of analysis, but image viewingis possible on all MR images) | Vendor-independent DICOM MRimages (specific requirements dependon type of analysis, but image viewingis possible on all MR images) |
| Imageasssessment | Manual and automatic contour detection Functional and regional analysis analysis of the heart ventricles Analysis of T2 and T2* relaxation values | Manual and automatic contour detection Functional analysis of LV and RV | (other assessment features not relevantfor equivalence) Analysis of T2 and T2* relaxation values |
| Image displayandmanipulation | 2D MR image Pan/zoom; magnify; maximize and minimize, scroll through slice stack; adjust window level, contrast, brightness | 2D MR image Pan/zoom; magnify; maximize and minimize, scroll through slice stack; adjust window level, contrast, brightness | 2D MR image 3D volume reconstruction Pan/zoom; magnify; maximize and minimize, scroll through slice stack; adjust window level, contrast, brightness |
| Correction types | Manual contour correction/propagation | Manual contour correction/propagation | Manual contour correction/propagation |
| Resultvisualization | Numerical Graph Bulls Eye View | Numerical Graph Bulls Eye View | Numerical Graph Bulls Eye View 3D view |
| Storage ofResults | Printout PDF DICOM SC XML Images (PNG, JPEG) Session state (reanalysis) | Printout DICOM SC CSV/spreadsheet Images (PNG, JPEG) | Printout Images XML DICOM SC PDF HTML |
| OperatingSystem | Windows | Windows | Windows |
Conformance Standards The device complies with the following conformance standards:
- ISO 14971:2007, Medical devices Application of risk management to ● medical devices
- NEMA PS 3.1 3.20 (2011), Digital Imaging and Communication in ● Medicine (DICOM) Set. (Radiology)
- . IEC 62304 First edition 2006-05, Medical device software - Software life cycle processes
- . IEC 62336:2007, Medical devices - Application of usability engineering to medical devices
{5}------------------------------------------------
Performance Data System requirements - derived from the intended use and indications for use - as well as risk control measures are verified by system testing. System testing showed that the system requirements were implemented correctly. For each analysis workflow a validation approach is created and the proper functioning of the algorithms is validated. For analysis workflows already implemented in earlier versions of CAAS MRV regression testing is performed to verify equivalence in numerical results. The validation of the tissue mapping algorithms used in the new analysis workflow Tissue Mapping demonstrated that the quantification of the tissue relaxation values (T2 and T2*) meet the accuracy and reproducibility requirements. Usability testing is performed a according with IEC 62366 to validate all analysis workflows of CAAS MRV and demonstrated that the user is able to use CAAS MRV for the purpose it was developed for. The test results demonstrate safety and effectiveness of CAAS MRV in relation to its intended use and that CAAS MRV is considered as safe and effective as the predicate devices. Substantial Equivalence The analysis workflows Functional Analysis in the previously cleared device CAAS MRV (K060941) is available in CAAS MRV and is similar in terms of intended use and indications for use and have the same technological characteristic and clinical use. The difference between these two devices is that the analysis workflow 'Tissue Mapping' has been added in CAAS MRV. With the addition of the Tissue Mapping workflow, the new CAAS MRV is, like the predicate CAAS MRV (K060941), intended to support the interventional cardiologist and radiologist with diagnoses. The Tissue Mapping workflow has a similar intended use and indications for use as the same functionality present in the MR-CT VVA System (K0140587). The feature is very similar in both control and presentation and yields the same results. From the comparison table and substantial quivalence analysis it can be Conclusion concluded that CAAS MRV is substantially equivalent to a combination of the predicate devices. Based on the application of risk management and performance testing inherent to PMI's quality system (compliant with recognized standards) CAAS MRV can be considered as safe and effective as its predicate devices and does not raise any new issues related to safety and effectiveness as compared to its predicate devices.
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).